Sugi Predict

Sugi Predict / Compounds / SCHEMBL144157

SCHEMBL144157

SCHEMBL144157

CC(C)Cn1c(N(C)C)nc2c(N)nc3ccccc3c21

nearest known ligand 0.58

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ TLR7 Q9NYK1 18/20 0.58
▸ TLR8 Q9NR97 6/20 0.58
▸ LMNA P02545 1/20 0.57
▸ POLB P06746 1/20 0.57
▸ HRH2 P25021 1/20 0.57
▸ ADRA1D P25100 1/20 0.57
▸ HTR2A P28223 1/20 0.57
▸ ADORA2A P29274 1/20 0.57
▸ ADRA1A P35348 1/20 0.57
▸ NUDT1 P36639 1/20 0.57
▸ HTR2B P41595 1/20 0.57
▸ PDE4D Q08499 1/20 0.57
▸ KCNH2 Q12809 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3274002 0.91 TLR7 (0.50) TLR7TLR8LMNAPOLBHRH2
SCHEMBL148087 0.89 TLR7 (0.57) TLR7TLR8LMNAPOLBHRH2
SCHEMBL4015090 0.89 TLR7 (0.50) TLR7TLR8LMNAPOLBHRH2
SCHEMBL144931 0.87 TLR7 (0.53) TLR7TLR8LMNAPOLBHRH2
SCHEMBL31379717 0.87 TLR7 (0.53) TLR7TLR8LMNAPOLBHRH2
SCHEMBL5808535 0.87 TLR7 (0.55) TLR7TLR8LMNAPOLBHRH2
SCHEMBL147570 0.86 TLR7 (0.54) TLR7TLR8LMNAPOLBHRH2
SCHEMBL29551159 0.86 TLR7 (0.54) TLR7TLR8LMNAPOLBHRH2
SCHEMBL4555124 0.86 TLR7 (0.48) TLR7TLR8LMNAPOLBHRH2
SCHEMBL144595 0.85 TLR7 (0.51) TLR7TLR8LMNAPOLBHRH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130096103-A1 IMIDAZOQUINOLINE COMPOUNDS NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2013-04-18 — — US claimed
US-20110217323-A1 IMIDAZOQUINOLINE COMPOUNDS NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2011-09-08 — — US claimed
US-20080213308-A1 Imidazoquinoline Compounds NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2008-09-04 — — US claimed
EP-1797091-A2 IMIDAZOQUINOLINE COMPOUNDS Novartis Vaccines and Diagnostics, Inc. (US) 2007-06-20 — — EP claimed
WO-2006031878-A2 IMIDAZOQUINOLINE COMPOUNDS NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) 2006-03-23 — — WO claimed
EP-4585610-A2 MAKING INFLUENZA VIRUS VACCINES WITHOUT USING EGGS Seqirus UK Limited (GB) 2025-07-16 — — EP disclosed
EP-4144368-B1 RSV IMMUNIZATION REGIMEN GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2025-02-26 — — EP disclosed
EP-3527224-B1 RSV IMMUNIZATION REGIMEN GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2025-02-26 — — EP disclosed
US-20250042951-A1 PRE-FUSION RSV F ANTIGENS NOVARTIS AG (CH) 2025-02-06 — — US disclosed
US-12139512-B2 Pre-fusion RSV F antigens GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2024-11-12 — — US disclosed
US-20240299537-A1 ADJUVANTED VACCINES WITH NON-VIRION ANTIGENS PREPARED FROM INFLUENZA VIRUSES GROWN IN CELL CULTURE SEQIRUS UK LTD (GB) 2024-09-12 — — US disclosed
US-20240299527-A1 RSV IMMUNIZATION REGIMEN NOVARTIS AG (CH) 2024-09-12 — — US disclosed
WO-2007052055-A1 ADJUVANTED VACCINES WITH NON-VIRION ANTIGENS PREPARED FROM INFLUENZA VIRUSES GROWN IN CELL CULTURE NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) 2007-05-10 — — WO disclosed
WO-2007052155-A2 INFLUENZA VACCINE WITH REDUCED AMOUNT OF OIL-IN-WATER EMULSION AS ADJUVANT NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) 2007-05-10 — — WO disclosed
WO-2007052058-A1 INFLUENZA VACCINES INCLUDING COMBINATIONS OF PARTICULATE ADJUVANTS AND IMMUNOPOTENTIATORS NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) 2007-05-10 — — WO disclosed
WO-2007041432-A2 CROSS-NEUTRALIZATION OF HCV WITH RECOMBINANT PROTEINS NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2007-04-12 — — WO disclosed
WO-2007011777-A2 SMALL ANIMAL MODEL FOR HCV REPLICATION NOVARTIS AG (CH) 2007-01-25 — — WO disclosed
WO-2006091517-A2 IMMUNOGENS FROM UROPATHOGENIC ESCHERICHIA COLI NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) 2006-08-31 — — WO disclosed
WO-2006089264-A2 PROTEINS AND NUCLEIC ACIDS FROM MENINGITIS/SEPSIS-ASSOCIATED ESCHERICHIA COLI NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) 2006-08-24 — — WO disclosed
WO-2006031878-A2 IMIDAZOQUINOLINE COMPOUNDS NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) 2006-03-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250042951-A1 PRE-FUSION RSV F ANTIGENS FURIN, CD69, LY96 TLR7 485/4885TLR8 1047/4885LMNA 480/4885
US-12139512-B2 Pre-fusion RSV F antigens FURIN, CD69, LY96 TLR7 485/4885TLR8 1047/4885LMNA 480/4885
US-20130096103-A1 IMIDAZOQUINOLINE COMPOUNDS IFNG, IRF3, MYD88 TLR7 13/4885TLR8 56/4885LMNA 4398/4885
US-20240299527-A1 RSV IMMUNIZATION REGIMEN IL5, IL15, IFNG TLR7 48/4885TLR8 77/4885LMNA 4368/4885
US-20110217323-A1 IMIDAZOQUINOLINE COMPOUNDS IFNG, IRF3, MYD88 TLR7 13/4885TLR8 56/4885LMNA 4398/4885
US-20240299537-A1 ADJUVANTED VACCINES WITH NON-VIRION ANTIGENS PREPARED FROM INFLUENZA VIRUSES GROWN IN CELL CULTURE LY96, PHOSPHO1, ASGR1 TLR7 73/4885TLR8 57/4885LMNA 2986/4885
US-20080213308-A1 Imidazoquinoline Compounds IFNG, IRF3, MYD88 TLR7 13/4885TLR8 56/4885LMNA 4398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.